Applied Physiology and Nutrition Research Group, Rheumatology Division, Faculty of Medicine, University of Sao Paulo, Sao Paulo, Brazil.
School of Health Sciences, Robert Gordon University, Aberdeen, United Kingdom.
Adv Nutr. 2019 May 1;10(3):452-463. doi: 10.1093/advances/nmy115.
β-Alanine supplementation is one of the world's most commonly used sports supplements, and its use as a nutritional strategy in other populations is ever-increasing, due to evidence of pleiotropic ergogenic and therapeutic benefits. Despite its widespread use, there is only limited understanding of potential adverse effects. To address this, a systematic risk assessment and meta-analysis was undertaken. Four databases were searched using keywords and Medical Subject Headings. All human and animal studies that investigated an isolated, oral, β-alanine supplementation strategy were included. Data were extracted according to 5 main outcomes, including 1) side effects reported during longitudinal trials, 2) side effects reported during acute trials, 3) effect of supplementation on circulating health-related biomarkers, 4) effect of supplementation on skeletal muscle taurine and histidine concentration, and 5) outcomes from animal trials. Quality of evidence for outcomes was ascertained using the Grading of Recommendations Assessment Development and Evaluation (GRADE) framework, and all quantitative data were meta-analyzed using multilevel models grounded in Bayesian principles. In total, 101 human and 50 animal studies were included. Paraesthesia was the only reported side effect and had an estimated OR of 8.9 [95% credible interval (CrI): 2.2, 32.6] with supplementation relative to placebo. Participants in active treatment groups experienced similar dropout rates to those receiving the placebo treatment. β-Alanine supplementation caused a small increase in circulating alanine aminotransferase concentration (effect size, ES: 0.274, CrI: 0.04, 0.527), although mean data remained well within clinical reference ranges. Meta-analysis of human data showed no main effect of β-alanine supplementation on skeletal muscle taurine (ES: 0.156; 95% CrI: -0.38, 0.72) or histidine (ES: -0.15; 95% CrI: -0.64, 0.33) concentration. A main effect of β-alanine supplementation on taurine concentration was reported for murine models, but only when the daily dose was ≥3% β-alanine in drinking water. The results of this review indicate that β-alanine supplementation within the doses used in the available research designs, does not adversely affect those consuming it.
β-丙氨酸补充剂是世界上使用最广泛的运动补剂之一,由于其具有多种有益的作用和治疗效果,其他人群对其作为一种营养策略的使用也在不断增加。尽管它的应用非常广泛,但人们对其潜在的不良反应的了解却很有限。为了解决这个问题,我们进行了一项系统的风险评估和荟萃分析。我们使用关键词和医学主题词在四个数据库中进行了搜索。所有研究β-丙氨酸单一、口服补充策略的人体和动物研究都被纳入。根据 5 个主要结局指标提取数据,包括 1)长期试验中报告的副作用,2)急性试验中报告的副作用,3)补充剂对循环健康相关生物标志物的影响,4)补充剂对骨骼肌牛磺酸和组氨酸浓度的影响,以及 5)动物试验的结果。使用推荐评估、制定与评价(GRADE)框架确定结局的证据质量,所有定量数据均使用基于贝叶斯原理的多层次模型进行荟萃分析。总共纳入了 101 项人体研究和 50 项动物研究。感觉异常是唯一报告的副作用,与安慰剂相比,补充β-丙氨酸的估计比值比(OR)为 8.9[95%可信区间(CrI):2.2,32.6]。与安慰剂组相比,接受活性治疗组的参与者的脱落率相似。β-丙氨酸补充剂会导致循环丙氨酸氨基转移酶浓度略有升高(效应大小,ES:0.274,CrI:0.04,0.527),但平均数据仍在临床参考范围内。对人体数据的荟萃分析显示,β-丙氨酸补充剂对骨骼肌牛磺酸(ES:0.156;95% CrI:-0.38,0.72)或组氨酸(ES:-0.15;95% CrI:-0.64,0.33)浓度没有主要影响。当每日剂量≥饮用水中 3%β-丙氨酸时,补充β-丙氨酸对鼠模型牛磺酸浓度有主要影响。本综述的结果表明,在现有研究设计中使用的剂量范围内,β-丙氨酸补充剂不会对使用者产生不良影响。